机构：[1]Cancer Institute/ Hospital, Chinese Academy of Medical Sciences, Beijing/CN,[2]Jilin Cancer Hospital, Changchun/CN,[3]Guangdong Lung Cancer Institute, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou/ CN,肿瘤治疗中心研究所肺肿瘤科广东省肺癌研究所广东省人民医院[4]Beijing Cancer Hospital/institute, Beijing/CN,[5]The 307Th Hospital of Chinese People’s Liberation Army, Beijing/CN,[6]The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou/CN,[7]Hubei Cancer Hospital, Wuhan/CN,[8]Nanjing General Hospital of Nanjing Military Command, Nanjing/CN,[9]Fourth Hospital of Hebei Medical University, Shijiazhuang/CN,[10]Department of Thoracic Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu/CN,[11]Peking University Third Hospital, Beijing/CN,[12]Chinese People’s Liberation Army General Hospital, Beijing/CN,[13]Fujian Cancer Hospital, Fuzhou/CN,[14]Shanghai Pulmonary Hospital, Tongji University, Shanghai/CN,[15]Cancer Center, Sun Yat-Sen University, Guangzhou/CN,[16]Imed Asia, Astrazeneca, Shanghai/CN
第一作者机构：[1]Cancer Institute/ Hospital, Chinese Academy of Medical Sciences, Beijing/CN,
推荐引用方式(GB/T 7714)：
J. Wang ,Y. Cheng ,Y. Wu ,et al.Gefitinib as First-Line Treatment of Plasma CtDNA EGFR Mutation-Positive NSCLC Detected by DdPCR: BENEFIT Study (CTONG1405)[J].JOURNAL OF THORACIC ONCOLOGY.2017,12(11):S1844-S1844.doi:10.1016/j.jtho.2017.09.544.
APA：
J. Wang,,Y. Cheng,,Y. Wu,,T. An,,H. Gao,...&Y. Sun.(2017).Gefitinib as First-Line Treatment of Plasma CtDNA EGFR Mutation-Positive NSCLC Detected by DdPCR: BENEFIT Study (CTONG1405).JOURNAL OF THORACIC ONCOLOGY,12,(11)
MLA：
J. Wang,,et al."Gefitinib as First-Line Treatment of Plasma CtDNA EGFR Mutation-Positive NSCLC Detected by DdPCR: BENEFIT Study (CTONG1405)".JOURNAL OF THORACIC ONCOLOGY 12..11(2017):S1844-S1844
医学